LXRX Lexicon Pharmaceuticals, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

LXRX [NASD]

Lexicon Pharmaceuticals, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	7.11	EPS (ttm)	0.19	Insider Own	0.60%	Shs Outstand	107.07M	Perf Week	-9.52%
Market Cap	145.70M	Forward P/E	-	EPS next Y	-0.97	Insider Trans	0.00%	Shs Float	105.84M	Perf Month	-8.28%
Income	39.30M	PEG	-	EPS next Q	0.26	Inst Own	-	Short Float	9.57%	Perf Quarter	-23.56%
Sales	320.30M	P/S	0.45	EPS this Y	197.90%	Inst Trans	-0.11%	Short Ratio	7.89	Perf Half Y	-42.17%
Book/sh	-0.10	P/B	-	EPS next Y	19.80%	ROA	10.10%	Target Price	-	Perf Year	-63.56%
Cash/sh	1.84	P/C	0.72	EPS next 5Y	-	ROE	48.20%	52W Range	1.34 - 5.33	Perf YTD	-67.95%
Dividend	-	P/FCF	-	EPS past 5Y	23.30%	ROI	40.70%	52W High	-75.05%	Beta	1.51
Dividend %	-	Quick Ratio	2.50	Sales past 5Y	69.70%	Gross Margin	99.20%	52W Low	-0.75%	ATR	0.08
Employees	184	Current Ratio	2.50	Sales Q/Q	-5.20%	Oper. Margin	15.70%	RSI (14)	32.92	Volatility	4.68% 5.52%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-197.80%	Profit Margin	12.30%	Rel Volume	0.73	Prev Close	1.36
Shortable	Yes	LT Debt/Eq	-	Earnings	Jul 30 BMO	Payout	0.00%	Avg Volume	1.28M	Price	1.33
Recom	2.80	SMA20	-9.11%	SMA50	-16.56%	SMA200	-37.44%	Volume	934,259	Change	-2.21%

Dec-11-19

Downgrade

Gabelli & Co

Buy → Hold

Nov-08-19

Downgrade

Citigroup

Buy → Neutral

$3 → $4

Sep-11-19

Upgrade

Gabelli & Co

Hold → Buy

Jul-29-19

Downgrade

Stifel

Buy → Hold

$10 → $4

Mar-25-19

Upgrade

Gabelli & Co

Sell → Hold

Jul-31-18

Reiterated

Stifel

Buy

$24 → $23

Feb-23-18

Downgrade

Needham

Buy → Hold

Feb-14-18

Downgrade

JP Morgan

Neutral → Underweight

$10

Mar-01-17

Reiterated

Wedbush

Outperform

$33 → $38

Mar-01-17

Reiterated

H.C. Wainwright

Buy

$26 → $27

Oct-07-16

Initiated

H.C. Wainwright

Buy

$26

Aug-05-16

Reiterated

Wedbush

Outperform

$30 → $31

Aug-02-16

Initiated

Citigroup

Buy

$21

Mar-02-16

Reiterated

Wedbush

Outperform

$26 → $28

Nov-09-15

Reiterated

Wedbush

Outperform

$19 → $26

Sep-28-15

Upgrade

Gabelli & Co

Sell → Hold

Sep-18-15

Downgrade

Gabelli & Co

Hold → Sell

Aug-10-15

Downgrade

JP Morgan

Overweight → Neutral

Aug-19-14

Downgrade

Gabelli & Co

Buy → Hold

Jun-26-12

Reiterated

Stifel Nicolaus

Buy

$3 → $4

Sep-23-20 06:43PM	Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness GlobeNewswire
Sep-14-20 09:46AM	A Look Into Healthcare Sector Value Stocks Benzinga +5.23%
Sep-08-20 04:05PM	Lexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera Therapeutics GlobeNewswire
Sep-04-20 08:00AM	Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain GlobeNewswire
Sep-03-20 06:00PM	Lexicon Pharmaceuticals to Participate in the Citi 15 Annual BioPharma Virtual Conference and the Wells Fargo 2020 Virtual Healthcare Conference GlobeNewswire
Aug-24-20 11:35AM	A Look Into Healthcare Sector Value Stocks Benzinga
Aug-10-20 11:52AM	5 Value Stocks To Watch In The Healthcare Sector Benzinga
Aug-03-20 07:25AM	GTCR and TerSera Therapeutics Announce Acquisition of Xermelo PR Newswire
Aug-02-20 09:54AM	What You Need To Know About The Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Analyst Downgrade Today Simply Wall St.
Jul-30-20 06:00PM	Lexicon Pharmaceuticals Inc (LXRX) Q2 2020 Earnings Call Transcript Motley Fool +14.94%
03:52PM	Is Lexicon Pharmaceuticals (NASDAQ:LXRX) A Risky Investment? Simply Wall St.
10:55AM	Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:15AM	Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program GlobeNewswire
07:10AM	Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO GlobeNewswire
07:00AM	Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update GlobeNewswire
Jul-23-20 07:00AM	Lexicon Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call and Webcast on July 30, 2020 GlobeNewswire -5.70%
Jul-22-20 12:32PM	Earnings Preview: Lexicon Pharmaceuticals (LXRX) Q2 Earnings Expected to Decline Zacks -6.99%
Jul-21-20 07:00AM	Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies in Type 2 Diabetes GlobeNewswire
Jul-20-20 07:00AM	Lexicon Pharmaceuticals Announces Poster Presentations at the Virtual Cholangiocarcinoma Foundation Annual Conference GlobeNewswire
Jul-14-20 01:19PM	5 Health Care Stocks Trading With Low Price-Earnings Ratios GuruFocus.com
Jul-04-20 02:02PM	Should You Buy Lexicon Pharmaceuticals, Inc. (LXRX)? Insider Monkey
Jun-13-20 11:01AM	Lexicon Pharmaceuticals Presents Clinical Data at 80th American Diabetes Association Scientific Sessions GlobeNewswire
Jun-11-20 05:22PM	Edited Transcript of LXRX earnings conference call or presentation 27-Apr-20 12:00pm GMT Thomson Reuters StreetEvents -6.47%
May-27-20 07:00AM	Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
May-13-20 05:30PM	Lexicon Pharmaceuticals Announces Preclinical Efficacy Data on Telotristat Ethyls Antiproliferative Effects Against Various Cancer Cell Lines GlobeNewswire
Apr-27-20 06:33PM	US Indexes Start the Week Higher GuruFocus.com +12.20%
04:24PM	Why Lexicon Pharmaceuticals Stock Soared Today Motley Fool
08:15AM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:43AM	Lexicon Pharmaceuticals: Q1 Earnings Insights Benzinga
07:00AM	LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE GlobeNewswire
Apr-22-20 05:41PM	Lexicon Pharmaceuticals to Host First Quarter 2020 Financial Results Conference Call and Webcast On April 27, 2020 GlobeNewswire -5.10%
Apr-20-20 10:04AM	The Lexicon Pharmaceuticals (NASDAQ:LXRX) Share Price Is Down 88% So Some Shareholders Are Rather Upset Simply Wall St.
Apr-07-20 07:00AM	LEXICON PHARMACEUTICALS TO HOST VIRTUAL ANNUAL MEETING OF STOCKHOLDERS ON APRIL 23, 2020 GlobeNewswire -5.91%
Mar-30-20 11:11AM	Edited Transcript of LXRX earnings conference call or presentation 12-Mar-20 12:00pm GMT Thomson Reuters StreetEvents
Mar-20-20 07:44AM	The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company Benzinga -14.83%
Mar-19-20 04:01PM	LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM GlobeNewswire
Mar-13-20 08:05AM	LEXICON PHARMACEUTICALS ANNOUNCES ADDITIONAL DATA ON TELOTRISTAT ETHYLS ANTIPROLIFERATIVE EFFECTS IN PATIENTS WITH CARCINOID SYNDROME GlobeNewswire +5.18%
Mar-12-20 01:40PM	Lexicon Pharmaceuticals: Q4 Earnings Insights Benzinga -14.98%
09:35AM	Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Misses Revenue Estimates Zacks
07:00AM	LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE GlobeNewswire
Mar-05-20 07:00AM	Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2019 Financial Results Conference Call and Webcast on March 12, 2020 GlobeNewswire -6.46%
Mar-04-20 12:30PM	Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for Zacks
Jan-24-20 03:00PM	Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyls Antiproliferative Effects in Patients With Carcinoid Syndrome GlobeNewswire
Jan-20-20 04:01PM	Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium GlobeNewswire
08:07AM	Is Lexicon Pharmaceuticals (NASDAQ:LXRX) Using Too Much Debt? Simply Wall St.
Jan-09-20 02:50PM	Top Biotech Stocks for Q1 2020 Investopedia
Jan-06-20 06:09PM	Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
Dec-20-19 08:31AM	Lexicon shares fall on diabetes study data MarketWatch
07:00AM	Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes GlobeNewswire
Dec-19-19 08:28PM	Were Hedge Funds Right About Betting On Lexicon Pharmaceuticals, Inc. (LXRX)? Insider Monkey
Dec-13-19 08:52AM	Implied Volatility Surging for Lexicon (LXRX) Stock Options Zacks
Dec-05-19 12:54PM	How Much is Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) CEO Getting Paid? Simply Wall St. +12.20%
07:00AM	Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211 GlobeNewswire
Dec-03-19 07:00AM	Lexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of TELE-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract Cancer GlobeNewswire
Dec-02-19 11:09AM	Why Lexicon Pharma Shares Are Moving Lower Benzinga -10.48%
09:57AM	FDA denies appeal of decision over Lexicon Pharmas diabetes drug Yahoo Finance Video
07:58AM	UPDATE: Lexicon Pharmaceuticals stock slides 31% after FDA denies appeal of decision relating to diabetes drug MarketWatch
07:00AM	Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDAs Office of New Drugs for Sotagliflozin in Type 1 Diabetes GlobeNewswire
Nov-26-19 04:01PM	Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire -6.02%
Nov-15-19 11:17PM	Edited Transcript of LXRX earnings conference call or presentation 7-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-14-19 08:09PM	Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
09:10AM	Are Investors Undervaluing Lexicon Pharmaceuticals (LXRX) Right Now? Zacks
Nov-13-19 08:39AM	Top Ranked Value Stocks to Buy for November 13th Zacks
Nov-07-19 11:15AM	Lexicon Pharmaceuticals (LXRX) Q3 Earnings and Revenues Beat Estimates Zacks
07:00AM	Lexicon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides a Business Update GlobeNewswire
Oct-31-19 04:01PM	Lexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019 GlobeNewswire
10:34AM	Lexicon Pharmaceuticals (LXRX) to Report Q3 Results: Wall Street Expects Earnings Growth Zacks
Oct-30-19 10:34AM	Is Lexicon Pharmaceuticals, Inc. (LXRX) Going to Burn These Hedge Funds? Insider Monkey
Oct-29-19 07:05AM	NASDAQ: LXRX Investor Notice: Update in Lawsuit against Lexicon Pharmaceuticals, Inc. announced by Shareholders Foundation ACCESSWIRE
Oct-15-19 11:29AM	Introducing Lexicon Pharmaceuticals (NASDAQ:LXRX), The Stock That Tanked 80% Simply Wall St.
Oct-13-19 05:15PM	New Sanofi CEO Looks to Shake Things Up GuruFocus.com
Oct-02-19 04:01PM	Lexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical Symposium GlobeNewswire
Sep-30-19 10:05AM	Small Caps Win in September: 5 Best ETFs & Stocks Zacks -12.37%
Sep-23-19 08:54AM	Are Options Traders Betting on a Big Move in Lexicon Pharmaceuticals (LXRX) Stock? Zacks -5.62%
Sep-18-19 08:42AM	Lexicon (LXRX) Catches Eye: Stock Jumps 7.3% Zacks +29.25%
Sep-15-19 11:18AM	The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck Benzinga
Sep-11-19 07:42PM	Woodlands-based pharma co. to receive $260M in drug dispute settlement American City Business Journals +27.91%
09:46AM	Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally Zacks
07:09AM	The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway Benzinga
Sep-10-19 04:51PM	Sanofi to pay Lexicon $260 mln for terminated partnership Reuters +21.13%
04:01PM	Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting GlobeNewswire
04:01PM	Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi GlobeNewswire
Sep-09-19 03:38PM	Market Sentiment Around Loss-Making Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Simply Wall St.
Sep-05-19 11:12AM	Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class? Motley Fool
Aug-30-19 07:00AM	Lexicon Pharmaceuticals To Present At Upcoming Investor Conference GlobeNewswire
Aug-27-19 01:59AM	Edited Transcript of LXRX earnings conference call or presentation 31-Jul-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-20-19 07:15PM	Lexicon Pharmaceuticals Inc (LXRX) President and CEO Lonnel Coats Bought $54,000 of Shares GuruFocus.com -6.38%
Aug-09-19 07:00AM	Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire +19.53%
Aug-08-19 05:23PM	Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes GlobeNewswire
Jul-31-19 11:36AM	Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates Zacks -18.67%
09:15AM	Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:00AM	Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update GlobeNewswire
Jul-30-19 12:59PM	Lexicon Pharmaceuticals Announces Date Change for Second Quarter 2019 Financial Results Conference Call and Webcast to July 31, 2019 GlobeNewswire
Jul-29-19 04:35PM	Why Cooper Tire & Rubber, Insperity, and Lexicon Pharmaceuticals Slumped Today Motley Fool -70.30%
12:14PM	Here's Why Lexicon Pharmaceuticals Is Collapsing Today Motley Fool
08:53AM	Lexicon's stock loses more than half its value after Sanofi's notice to end alliance MarketWatch
Jul-27-19 05:05AM	Sanofi ends partnership with Lexicon to develop add-on pill for diabetes Reuters
Jul-26-19 05:58PM	UPDATE 1-Sanofi ends partnership with Lexicon to develop add-on pill for diabetes Reuters
05:15PM	Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista (Sotagliflozin) Type 2 Diabetes Phase 3 Program GlobeNewswire
05:05PM	Sanofi ends partnership with Lexicon to develop diabetes drug Reuters

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SOBECKI CHRISTOPHER J	Director	Apr 26	Option Exercise	0.00	3,466	0	140,759	Apr 27 04:48 PM
Swain Judith L	Director	Apr 26	Option Exercise	0.00	3,466	0	16,368	Apr 27 04:49 PM
Palantoni Frank	Director	Apr 26	Option Exercise	0.00	3,466	0	16,368	Apr 27 04:48 PM
NIES ALAN S	Director	Apr 26	Option Exercise	0.00	3,466	0	17,082	Apr 27 04:47 PM
DEBBANE RAYMOND	Director	Apr 26	Option Exercise	0.00	3,466	0	316,883	Apr 27 04:45 PM
LEFKOWITZ ROBERT J MD	Director	Apr 26	Option Exercise	0.00	3,466	0	16,368	Apr 27 04:46 PM
BARKER SAM L	Director	Apr 26	Option Exercise	0.00	3,466	0	55,653	Apr 27 04:44 PM
Amouyal Philippe	Director	Apr 26	Option Exercise	0.00	3,466	0	16,368	Apr 27 04:43 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience